Beverley Moore practises in all areas of intellectual property litigation at Borden Ladner Gervais LLP, with a focus on patent litigation and applications under the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations). She also advises clients on regulatory issues such as listing patents on the Patent Register, reporting patents to the Patented Medicines Prices Review Board (PMPRB), and the Register of Innovative Drugs as it relates to data protection. Beverley also advises on Access to Information (ATI) requests, in particular those made to Health Canada by pharmaceutical clients. In addition, Beverley advises on patent portfolio management, patentability, validity and freedom-to-operate issues, and aids in the prosecution of patent applications in Canada. Currently, Beverley is also advising and consulting on the implementation and application of the intellectual property provisions of the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union.
Beverley has been an advocate before the Federal Courts, the Patented Medicine Prices Review Board and the Supreme Court of Canada. Beverley is a co-editor of Carswell's Consolidated Intellectual Property Statutes and Regulations, and co-author of the book's "Patents – Year in Review" article. Beverley and her colleagues, Chantal Saunders, Adrian Howard and Jillian Brenner, publish a weekly IP Bulletin, summarizing recent IP cases and industry news of note. In addition, Beverley is a member of BIOTECanada's Health Advisory Board and Subsequent Entry Biologics Task Force, and has lobbied politicians on biotechnology issues. Beverley also sits on the editorial board of the Canadian Intellectual Property Review Beverley's M.Sc. research involved mechanistic studies with Vitamin D analogues.